Role of Marginal Zone B Lymphocytes in Invariant NKT Cell Activation

Emilie Bialecki, Christophe Paget, Josette Fontaine, Monique Capron, François Trottein and Christelle Faveeuw

*J Immunol* 2009; 182:6105-6113;
doi: 10.4049/jimmunol.0802273
http://www.jimmunol.org/content/182/10/6105

---

**References**
This article cites 60 articles, 37 of which you can access for free at:
http://www.jimmunol.org/content/182/10/6105.full#ref-list-1

**Subscription**
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts

---

*The Journal of Immunology* is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.
Role of Marginal Zone B Lymphocytes in Invariant NKT Cell Activation

Emilie Bialecki,*†‡ Christophe Paget,*†‡ Josette Fontaine,*†‡ Monique Capron,*†‡ François Trottein,*†‡ and Christelle Faveeuw2*†‡

Splenic marginal zone B (MZB) lymphocytes represent, along with dendritic cells (DC) a first line of defense against blood-borne pathogens. MZB cells express high levels of MHC class II and CD1d molecules but so far their ability to activate and orientate conventional and innate-like T lymphocytes, such as invariant NKT (iNKT) cells, is still elusive. In the present study, we show that murine MZB cells proliferate, mature phenotypically, and secrete cytokines in response to TLR (except TLR3) agonists. When pulsed with OVA peptide (but not whole OVA), MZB cells promote the release of IFN-γ and IL-4 by Ag-specific CD4+ T lymphocytes and their stimulation with the TLR9 agonist CpG oligodeoxynucleotide (ODN), a potent MZB cell activator, biases them toward more Th1 inducers. Unlike DC, CpG ODN-stimulated MZB cells fail to stimulate iNKT cells. Although able to activate iNKT hybridomas, MZB cells sensitized with free α-galactosylceramide (α-GalCer), a CD1d-restricted glycolipid Ag, do not directly activate ex vivo sorted iNKT cells unless DC are added to the culture system. Interestingly, MZB cells amplify the DC-mediated activation of iNKT cells and depletion of MZB cells from total splenocytes strongly reduces iNKT cell activation (cytokine production) in response to α-GalCer. Thus, DC and MZB cells provide help to each other to optimize iNKT cell stimulation. Finally, in vivo transfer of α-GalCer-loaded MZB cells potently activates iNKT and NK cells. This study confirms and extends the concept that MZB cells are important players in immune responses, a property that might be exploited. The Journal of Immunology, 2009, 182: 6105–6113.

The innate immune system is central in maintaining the integrity of an organism constantly challenged by pathogens. Among innate immune cells, splenic marginal zone B (MZB) lymphocytes are strategically located to respond to blood-borne microorganisms and viruses and to play an important role in host defense (1–3). Upon Ag encounter via the BCR, MZB cells swiftly produce large quantities of IgM Abs that mediate protection at early stages of infection (1, 4). Along with their ability to produce Abs, MZB cells also affect the T cell response. For instance they can migrate into the splenic follicles to deliver immune complexes to follicular dendritic cells (DC), a mechanism that is crucial for the initiation of the adaptive immune response (5). In addition, and unlike follicular B cells, MZB cells have a unique capability to prime naive CD4+ T lymphocytes and drive their differentiation into effector cells. Indeed, upon in vivo Ag uptake via their BCR, MZB cells directly promote Ag-specific CD4+ T cell proliferation and cytokine production (6). Along with these studies, recent evidence suggests a role for innate sensors in MZB cell-mediated immune responses. MZB cells are indeed well equipped in TLRs and their stimulation leads to cell proliferation, maturation (i.e., cytokine production) and Ab production (7–9). However, the consequences of TLR triggering on the ability of MZB cells to activate and orientate conventional as well as innate-like T lymphocytes, including invariant NKT (iKNT), has not yet been examined.

iNKT cells, the major subset of NKT cells, are defined by the canonical Var14-Ja18 TCRα-chain in mice (Var24-Jα18 in humans) and recognize exogenous and self (glyco)lipid Ags presented by the non-classical class I molecule CD1d expressed on APC (10, 11). Upon primary stimulation, in particular in response to the non-mammalian glycolipid α-galactosylceramide (α-GalCer), iNKT cells produce large amounts of immunoregulatory cytokines, including IFN-γ and IL-4, that lead to downstream activation of DC, NK cells, B cells, and conventional T cells (10, 12). During stress conditions (i.e., infection), iNKT cells have also been shown to release cytokines to shape immune responses, with beneficial or detrimental outcomes depending on the nature and site of stimulation (10–12). During infection, it is likely that TLR activation in sentinel cells, such as DC, plays a key role in the indirect activation of iNKT cells (13–16). A recently described aspect of iNKT cell function is their ability to regulate humoral responses during infection and autoimmune diseases (17–23). Studies performed in the human and mouse systems reported that iNKT cells can help B cells to mature, proliferate, and produce Abs (both IgG and IgE) through a CD1d-dependent mechanism (24–28). It was also shown that co-administration of α-GalCer increased Ig responses to T-dependent or T-independent Ags, thus underlining the adjuvant properties of α-GalCer on Ab production (26, 28–31). More recently, some reports demonstrated that
\(\alpha\)-GalCer targeting to the BCR leads to enhanced B cell responses in vivo (32–34). In this case, B lymphocytes efficiently present \(\alpha\)-GalCer to iNKT cells promoting their activation, thereby enhancing Ab production.

Interestingly, MZB cells have a pre-activated phenotype and highly express MHC class II and CD1d molecules as well as co-stimulatory molecules (2, 4, 35). In addition, Stetson et al. reported (36), in the expression MHC class II and CD1d molecules as well as co-stimulatory enhancing Ab production.

In vivo (32–34). In this case, B lymphocytes efficiently present CD19

Preparation of bone marrow-derived DC
DC were generated from the bone marrow of mice, as previously described (38). In brief, bone marrow-derived cells were cultured in RPMI 1640 medium supplemented with 10% FCS and 1% of supernatant from a GM-C57BL/6 mice has been already described (37). Mice were bred in our own facility in pathogen-free conditions. Animals were handled and housed in accordance with the guidelines of the Pasteur institute Animal Care and Use Committee.

Preparation of spleen cells and MZB cell sorting
Splenocytes were harvested and mechanically homogenized. After washes, RBC were removed with lysis buffer (155 mM N\textsubscript{H}4Cl (pH 7.4), 10 mM NaHCO\textsubscript{3}, 0.1 mM EDTA). For sorting of MZB cells, spleen mononuclear cells (MNC) from WT mice, which contain approximately 2–3% of CD19\textsuperscript{+}CD21\textsuperscript{high}CD23\textsuperscript{low} cells, were labeled with allopurinol-conjugated anti-CD19, PE-conjugated anti-CD21, FITC-conjugated anti-CD23, and FITC-conjugated CD21 mAbs. After cell surface labeling and washing, cells were electronically sorted using a FACS Aria (BD Biosciences). Sorted CD19\textsuperscript{+}CD21\textsuperscript{high}CD23\textsuperscript{low} cells were ≥99% pure (see Fig. 1).
Results

TLR stimulation elicits proliferation and phenotypic maturation of MZB cells with distinct cytokine production

During stress conditions (i.e., infection), activation of TLR in APC, including DC, is important to promote innate and acquired immune responses (39). The impact of TLR activation on MZB cells is however ill-defined. Using canonical agonists, we analyzed the response of MZB cells to diverse TLR agonists in terms of phenotypic maturation and cytokine production. For this, MZB cells were sorted on the basis of CD19, CD21, and CD23 staining (99% purity, Fig. 1A) and exposed to optimal doses of TLR agonists known to induce DC maturation (14). Different activation parameters were analyzed following overnight stimulation. As depicted in Fig. 1B, sorted MZB cells proliferate in response to all tested TLR agonists, except poly(I:C) (TLR3), thus confirming recent data (8). MZB cell expansion was accompanied by cytokine secretion. Indeed, all TLR agonists (except poly(I:C)) induced IL-6 and IL-10 production by MZB cells, R848 (TLR7/8) and CpG ODN (TLR9) being the most potent inducers. These results confirm and extend recent data reporting IL-6 and IL-10 secretion by MZB cells following TLR2, 4, (7/8, our study) and 9 stimulation (7). On the other hand, IL-12p40, TNF-α, IFN-γ, IL-4 and IFN-α were not detected whatever the agonist used (Fig. 1B and not shown). Interestingly, MZB cells secrete IFN-β, but only in response to CpG ODN.

We then investigated whether TLR agonists could lead to phenotypic maturation of MZB cells (Fig. 2). Although unstimulated MZB cells express a relatively high basal level of Ag presenting (MHC class II, CD1d) and co-stimulatory (CD40, CD86) molecules, TLR stimulation (except TLR3) leads to an increased MHC class II, CD40 and CD86 expression, whereas CD1d expression is unmodified. In conclusion, our data show that, except for poly(I:C), MZB cells stimulated with TLR agonists display similar proliferation and phenotypic maturation but differentially secrete cytokines, according to the TLR agonist used. Since CpG ODN is the most effective agonist to promote cytokine production, including IFN-β secretion, we concentrated on CpG ODN for the rest of the study.

OVA peptide-pulsed MZB cells activate Ag-specific CD4+ T lymphocytes

We next evaluated the ability of unstimulated and CpG ODN-stimulated MZB cells to present Ag to CD4+ T lymphocytes. As professional APC, DC were used as a positive control. Unstimulated or CpG ODN-stimulated MZB cells or DC were sensitized
with whole OVA protein or OVA peptide and, after extensive washing, were cocultured with purified OVA-specific naive CD4\(^+\) T cells. After 5 days, T cells were re-stimulated with anti-CD3 and cytokine production was measured 2 days later. In this setting, OVA and OVA peptide-sensitized DC induced IFN-\(\gamma\) production by CD4\(^+\) T lymphocytes whereas, in agreement with Constant et al. (40), IL-4 production was only detected in response to OVA-loaded DC (Fig. 3). Addition of CpG ODN further increased IFN-\(\gamma\) production in response to both OVA protein and peptide whereas IL-4 production was decreased with OVA-sensitized DC. In contrast to DC, OVA-sensitized MZB cells did not elicit cytokine production by CD4\(^+\) T lymphocytes. Interestingly, OVA peptide-loaded MZB cells induced IFN-\(\gamma\) as well as IL-4 production by CD4\(^+\) T lymphocytes and addition of CpG ODN during the sensitization phase amplified IFN-\(\gamma\) release. Thus, MZB cells pulsed with OVA peptide, but not whole OVA, activate Ag-specific CD4\(^+\) T lymphocytes to secrete cytokines and CpG ODN stimulation favors a more pronounced Th1 response.

MZB cells present \(\alpha\)-GalCer to iNKT cell hybridomas but fail to directly activate ex vivo sorted iNKT cells

As previously described, MZB cells express copious amount of CD1d, this expression being higher than in DC ((41) and data not shown). For this reason, we investigated whether MZB cells could activate iNKT cells in response to free \(\alpha\)-GalCer as well as in response to CpG ODN, an indirect activator of iNKT cells (14, 42). To avoid cell activation, iNKT cells were sorted on the basis of CD5 and NK1.1 staining. Purified MZB cells and DC were exposed to \(\alpha\)-GalCer or to CpG ODN, extensively washed, and cocultured with splenic CD5\(^+\) NK1.1\(^+\) (NKT) cells. As expected, \(\alpha\)-GalCer-loaded DC promoted IFN-\(\gamma\) and IL-4 production by splenic NKT cells (Fig. 4A). In stark contrast, NKT cells...
failed to release IFN-γ and IL-4 in response to α-GalCer-sensitized MZB cells. In response to CpG ODN, DC elicited a moderate IFN-γ production by splenic NKT cells whereas MZB cells were unable to activate them. Since splenic CD5+ NK1.1+ cells contain ~50% of non-iNKT cells ((43) and data not shown) that could interfere with iNKT cell activation, hepatic CD5+ NK1.1+ cells (~90% iNKT cells) (Ref. 44); and data not shown) were used in our coculture system. As expected, α-GalCer or CpG ODN-treated DC promoted IFN-γ secretion by iNKT cells as well as IL-4 in response to α-GalCer-sensitized DC (Fig. 4A). However, at the doses used, α-GalCer-pulsed or CpG ODN-treated MZB cells did not elicit IFN-γ or IL-4 by hepatic CD5+ NK1.1+ cells (Fig. 4A).

Next, we tested the capacity of MZB cells to activate iNKT cell hybridomas, a process that is independent upon innate cytokines or co-stimulation. As expected, α-GalCer-sensitized DC promoted IL-2 secretion by the DN32.D3, 2C12, and 5KC hybridomas (Fig. 4B). Interestingly, α-GalCer-sensitized MZB cells also induced IL-2 release by all iNKT cell hybridomas. This activation was CD1d-dependent since no IL-2 production was detected when CD1d−/− DC or CD1d−/− MZB cells were used. Of note, albeit strongly reduced (~70%), the DN32.D3 hybridoma produced a residual amount of IL-2 when cocultured with α-GalCer-loaded CD1d−/− MZB cells. This phenomenon might be due to α-GalCer autopresentation by the DN32.D3 hybridoma itself (45). Finally, although CpG ODN-sensitized DC induced IL-2 production by iNKT cell hybridomas, CpG ODN-sensitized MZB cells failed to do so (data not shown). In conclusion, despite high level of CD1d expression, α-GalCer or CpG ODN-sensitized MZB cells are unable to directly stimulate ex vivo-sorted splenic or hepatic iNKT cells. However, their ability to activate, in a CD1d-dependent manner, iNKT cell hybridomas suggests that, when exposed to free α-GalCer, MZB cells can present α-GalCer to iNKT cells.

α-GalCer-loaded MZB cells activate iNKT cells in the presence of DC

The inability of α-GalCer-sensitized MZB cells to directly stimulate ex vivo sorted iNKT cells suggests that additional soluble and/or membrane bound co-factors are necessary. Since DC are well equipped to induce iNKT cell activation, we hypothesized that they might help MZB cells to promote cytokine release by iNKT cells. As shown in Fig. 5, addition of untreated DC triggered IFN-γ and IL-4 secretion by iNKT cells when cocultured with α-GalCer-pulsed MZB cells. To investigate the role of DC-expressed CD1d in this phenomenon, CD1d−/− DC were used. As shown in Fig. 5, iNKT cell production of IFN-γ and IL-4 was strongly, but not completely, reduced in the presence of CD1d−/− DC (~70% and ~55%, respectively). As a whole, these data suggest that DC help MZB cells to promote iNKT cell activation in

FIGURE 5. Addition of DC restores IFN-γ and IL-4 production by iNKT cells cocultured with α-GalCer-loaded MZB cells. MZB cells were loaded with α-GalCer and then cocultured with CD5+ NK1.1+ cells for 48 h in the presence or absence of unloaded WT or CD1d−/− DC. Cytokine production was assessed by ELISA. One experiment out of three is shown. Results represent the mean ± SD of duplicates. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

FIGURE 6. MZB cells participate to optimal iNKT cell activation. A, α-GalCer-loaded DC were cocultured with hepatic CD5+ NK1.1+ cells for 48 h in the presence or absence of unstimulated or α-GalCer-sensitized MZB cells. IFN-γ and IL-4 production were quantified by ELISA. B, Splenocytes were stained with CD19, CD21, and CD23 mAb and then MZB cells were depleted using the FACSria. The upper panel shows dot plots representing the proportion of MZB cells, among CD19+ cells, before and after cell depletion. Control or MZB-depleted splenocytes were cultured for 48 h with grading doses of α-GalCer and cytokine production in the supernatant was evaluated by ELISA (lower panel). Data represent the mean ± SD of three independent experiments (A), *, p < 0.05; **, p < 0.01; ***, p < 0.001. Shown is a representative experiment out of three and results represent the mean of duplicate ± SD (B).
part through α-GalCer cross-presentation or through self ligand (CD1d dependency) and in part through DC-expressed co-factors.

**MZB cells optimize DC-mediated iNKT cell activation**

To investigate whether MZB cells could also help DC to trigger iNKT cell activation, MZB cells were added to co-cultures containing α-GalCer-loaded DC and hepatic CD5+ NK1.1+ cells. Interestingly, addition of naive MZB cells moderately (~25%) increased IFN-γ, but not IL-4, release by iNKT cells (Fig. 6A). Moreover, α-GalCer-loaded MZB cells amplified IFN-γ and IL-4 responses (~50% and 40%, respectively). To further demonstrate the cooperative role of MZB cells in iNKT cell activation, splenocytes were electronically depleted in MZB cells (Fig. 6B, upper panel) and exposed to grading doses of α-GalCer. Of note, MZB cell depletion did not modify the proportion of DC, iNKT cells and NK cells (data not shown). As represented in Fig. 6B (lower panel), and relative to the control, depletion of MZB cells decreased IFN-γ and IL-4 production by splenocytes. Thus, MZB cells optimize the activation of iNKT cells in response to α-GalCer.

---

**α-GalCer-loaded MZB cells activate iNKT cells in vivo**

We next investigated whether α-GalCer-loaded MZB cells could activate iNKT cells in vivo. Unloaded or α-GalCer-loaded MZB cells were injected i.v. into recipient mice and the activation state of splenic and liver NKT cells was determined 3 h later by intracellular FACS staining. Injection of α-GalCer-sensitized MZB cells induced a decreased frequency of CD5+ NK1.1+ cells in the spleen (0.8% vs 0.5%) and the liver (20.2% vs 11.4%) (Fig. 7A), an effect likely due to NK1.1 down-modulation (46). Interestingly, compared with unloaded MZB cells, α-GalCer-loaded MZB cells promoted an increased frequency of NKT cells positive for IFN-γ and IL-4 in the spleen and the liver. This increased frequency was still observed 12 h post-injection (data not shown). Moreover, 12 h post-injection, splenic and hepatic CD5+ NK1.1+ (NK cells) also labeled positively for IFN-γ whereas 3 h post injection, only hepatic NK cells produced IFN-γ intracellularly (Fig. 7B). Finally, analysis of cytokine concentration in the serum of mice injected with α-GalCer-loaded MZB cells revealed the presence of IL-4 and...
IFN-γ (Fig. 7C). Altogether, our data show that MZB cells efficiently activate the iNKT/NK cell pathway in vivo.

**Discussion**

MZB cells are ideally poised in the spleen to sense blood-borne microorganisms and to participate in innate/acquired immune responses. We showed that, in response to all tested TLR agonists (except poly(I:C)), MZB cells proliferate and exhibit a similar phenotypic maturation process characterized by an increased expression of MHC class II, CD40, and CD86 molecules. On the other hand, MZB cells display a different cytokine profile according to the TLR agonist used, with R848 (TLR7) and CpG ODN (TLR9) as main IL-6 and IL-10 inducers. These results are in line with three recent studies reporting that MZB cells can sense TLR agonists to mature, with the exception of TLR3, a molecular sensor for double-stranded (viral) RNA (7–9). In addition, we show for the first time that MZB cells produce IFN-β, a key anti-viral cytokine, in response to CpG ODN (but not to other agonists). Together, our results suggest that, like DC, MZB cells can become activated in response to a large panel of TLR agonists, a property that might be important to promote innate and adaptive immune responses during infection.

Some reports have suggested that MZB cells contribute to the development of T cell responses (6, 47). Our in vitro data show that MZB cells can present peptide Ag to trigger T cell activation, a property possibly linked to the high level of MHC class II, CD40, and CD86 expression (4). Although less flexible than DC, activation of TLR9 in MZB cells polarizes the T cell response toward a more Th1 direction. This finding cannot be explained by IL-12 induction following CpG ODN stimulation and rather suggests the involvement of other Th1-promoting soluble or membrane-bound (i.e., CD40) factor(s). On the other hand, MZB cells sensitized with the whole OVA protein do not activate CD4+ T lymphocytes, a phenomenon likely due to the low frequency of Ag (OVA) specific MZB cells in the system. Attanavanitch et al. elegantly reported that MZB cells from transgenic mice expressing BCR specific for hen egg lysozyme (but not from WT animals) efficiently activate ex vivo Ag-specific CD4+ T cells (6). Altogether, these results infer that MZB cells can present peptide Ag to specific T lymphocytes but, unlike DC, fail to do so unless Ag internalization is facilitated by BCR.

Having established that peptide-pulsed MZB cells can stimulate conventional T cells, we next studied their capacity to activate iNKT cells in response to free α-GalCer. Recently, using total B lymphocytes (32–34), and to a lower extent MZB cells (32, 34), it has been elegantly demonstrated that specific internalization of α-GalCer via the BCR efficiently activates iNKT cells that in turn provide cognate help for Ab production. While this mode of BCR-mediated Ag internalization might be of importance in the case of particulate antigenic lipids, the effect of soluble (non-particulate) antigenic lipids on MZB cell-mediated activation of iNKT cell remains uncharted. Despite a high level of CD1d, CD40, and CD86 expression on their surface, MZB cells pulsed with free α-GalCer fail to directly activate ex vivo sorted splenic and hepatic CD5+ NK1.1+ cells, at least in terms of cytokine (IL–4 and IFN-γ) release. Of note, IL-17 and IL-21, two cytokines recently described to be produced by iNKT cells (48, 49) were also absent in the coculture supernatants (data not shown). To fully eliminate a potential interfering role of non-iNKT cells in our setting, we also utilized CD1d/α-GalCer tetramer+ TCRβ+ cells in the coculture system, although this procedure is known to partially activate iNKT cells (14, 50). In this condition, α-GalCer-sensitized MZB cells also failed to directly activate primary (ex vivo sorted) iNKT cells (data not shown). On the other hand, and in agreement with (32) who used total B lymphocytes, our data show that α-GalCer-loaded MZB cells activate, in a CD1d-dependent manner, iNKT cell hybridomas. It is known that TCR-dependent activation of iNKT cell hybridomas can occur without any other co-stimulation. This suggests that, probably by direct surface loading of CD1d, soluble α-GalCer can be presented by MZB cells to trigger TCR-mediated signals in iNKT cells. However, MZB cells lack co-stimulatory factors (i.e., innate cytokines such as IL-12) necessary to achieve activation of primary iNKT cells in vitro (see below). The ability of TLR9-stimulated MZB cells to activate iNKT cells was also assessed. We showed that, unlike TLR9-activated DC (14), MZB cells stimulated with CpG ODN do not activate either primary iNKT cells or iNKT cell hybridomas, a phenomenon probably due to the absence of CD1d-restricted endogenous glycolipid biosynthesis in MZB cells.

We next questioned whether DC could help MZB cells to activate primary iNKT cells. We showed that addition of untreated DC restores IFN-γ and IL-4 production by iNKT cells cocultured with α-GalCer-loaded MZB cells. Surprisingly, this process is strongly dependent on CD1d expression on DC suggesting that the latter might cross present α-GalCer to iNKT cells, as previously reported (51). Indeed, these authors demonstrated that splenic CD8α− DC can pick up α-GalCer from dying tumor cells in vivo to cross present it to iNKT cells. Another possibility is that DC help MZB cells by presenting (a) CD1d-restricted self-Ag(s), as recently suggested by Cheng et al. (52). Finally, although reduced, CD1d−/− DC still help MZB cells to activate iNKT cells suggesting that co-stimulatory factors are also necessary. The nature of the candidate(s) is still under investigation. Using specific mAb, we have excluded IL-12 as a potential candidate (not shown) and attempts are now underway to identify its (their) nature. We next questioned whether MZB cells could help α-GalCer-loaded DC to modulate iNKT cell activation. Addition of naive MZB cells in our culture system significantly increased IFN-γ, but not IL-4, release by iNKT cells, a phenomenon probably due to high CD40 expression on MZB cells, the latter being known to enhance IFN-γ production by iNKT cells (53). This additive effect, as well as enhanced IL-4 release, was also observed after addition of α-GalCer-loaded MZB, thus suggesting a cooperative role of MZB cells in iNKT cell activation. Importantly, this assumption is supported by the fact that MZB-depleted spleen cells produce less cytokines when exposed to α-GalCer, relative to total splenocytes (Fig. 6B). Thus, DC and MZB cells appear to cooperate, at least in vitro, to achieve optimal iNKT cell activation in response to α-GalCer. This observation might be relevant in vivo and is consistent with the anatomical co-localization of DC, MZB cells and iNKT cells in the marginal zone of the spleen (36). Finally, we report for the first time that α-GalCer-loaded MZB cells can activate iNKT cells in vivo to produce IFN-γ and IL-4, a process that leads to the bystander activation of NK cells. It is likely that, in this setting, accessory cells including DC intervene in this activation pathway. Our results support a role for MZB cells in iNKT cell activation in vivo and are in line with previous studies reporting that α-GalCer-loaded M lymphocytes efficiently activate iNKT cells in vivo (54–56). These data do not run counter those from Bezbradica et al. (57). Indeed, using B cell-deficient mice, these authors reported that M lymphocytes suppressed DC-mediated iNKT and NK cell activation after in vivo injection of free α-GalCer. The experimental approaches used in both studies are different and the use of MZB cell-deficient mice would be useful to more fully assess the in vivo functions of MZB cells. Some studies reported that injection of mAbs specific for LFA-1 and VLA-4 specifically depletes the spleen from MZB cells (17, 58 and data not shown). Although very promising, this approach is not exploitably since
blockade of LFA-1 also abrogates DC-mediated iNKT cell activation (Ref. 59, 60 and data not shown).

In conclusion, our study provides evidence that MZB cells react (i.e., cytokine release) to a large panel of TLR agonists and that CpG ODN-stimulated peptide-pulsed MZB cells polarize CD4 + T lymphocytes toward a more Th1 direction. When sensitized with soluble α-GalCer, MZB cells stimulate the release of both IFN-γ and IL-4 by iNKT cells, but only in the presence of accessory cells (DC). The later finding strongly suggests that MZB cells have the potential, under certain circumstances (i.e., exogenous activation by α-GalCer), to condition iNKT cell functions in vivo. This, and the fact that BCR facilitates the uptake of particulate lipid Ag and its transport to CD1d-containing endocytic compartments reinforce the hypothesis that MZB cell/iNKT cell interplays may be of particular importance, for instance for Ab production. Whether MZB cells influence the immune response during infection or after exogenous activation by α-GalCer is still unknown and awaits further studies.

Acknowledgments

We greatly acknowledge Dr. L. Van Kaer (Vanderbilt University, Nashville, TN) for the gift of CD1d−/−C57BL/6 mice. We thank Dr A. Bendelac (University of Chicago, IL) for the gift of the NKT cell hybridoma DN32.D3 and 2C12 and Dr L. Gapin (University of Colorado Health Science Center, Denver, CO) for the gift of the NKT cell hybridoma 5KC. Drs. L. Gapin and T. Mallevaey (Denver, CO) are acknowledged for the helpful discussion and C. Vendeville (Inserm U547, Lille, France) for technical assistance.

Disclosures

The authors have no financial conflict of interest.

References


